Hvilken er prisen på Fresh Tracks Therapeutics, Inc. (FRTX)

Prisen på Fresh Tracks Therapeutics, Inc. (FRTX) er $0.94

Hva er markedsverdien på Fresh Tracks Therapeutics, Inc. (FRTX)

Markedsverdien på Fresh Tracks Therapeutics, Inc. (FRTX) er $2.73M

Fresh Tracks Therapeutics, Inc. (FRTX) Utestående Aksjer

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

År	Utestående aksjer	Endre
2026 (TTM)	5.91M	0.00%
2023	5.91M	110.56%
2022	2.81M	57.33%
2021	1.78M	227.63%
2020	544.76K	710.92%
2019	67.18K	-3.12%
2018	69.34K	69.47%
2017	40.91K	28.64%
2016	31.81K	9.20%
2015	29.13K	3.33%
2014	28.19K	2.24%
2013	27.57K	1.02%
2012	27.29K	19.35%
2011	22.87K	19.88%
2010	19.07K	27.61%
2009	14.95K	18.14%
2008	12.65K	1.70%
2007	12.44K	24.67%
2006	9.98K	27.89%
2005	7.80K	8.31%
2004	7.20K	12.95%
2003	6.38K	0.06%
2002	6.37K	0.24%
2001	6.36K	1.74%
2000	6.25K	0.00%

År

Utestående aksjer

Endre

2026 (TTM)

5.91M

0.00%

2023

5.91M

110.56%

2022

2.81M

57.33%

2021

1.78M

227.63%

2020

544.76K

710.92%

2019

67.18K

-3.12%

2018

69.34K

69.47%

2017

40.91K

28.64%

2016

31.81K

9.20%

2015

29.13K

3.33%

2014

28.19K

2.24%

2013

27.57K

1.02%

2012

27.29K

19.35%

2011

22.87K

19.88%

2010

19.07K

27.61%

2009

14.95K

18.14%

2008

12.65K

1.70%

2007

12.44K

24.67%

2006

9.98K

27.89%

2005

7.80K

8.31%

2004

7.20K

12.95%

2003

6.38K

0.06%

2002

6.37K

0.24%

2001

6.36K

1.74%

2000

6.25K

0.00%

Selskap	Utestående aksjer	Forskjell	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	4,194.08%	US
Argenx SE ARGX.US	62.19M	951.71%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	0.00	-100.00%	BE

Selskap

Utestående aksjer

Forskjell

Land